Drugs / HS-20122
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07645222 | Jun 2026 → Oct 2028 expected | lung cancer | Hansoh BioMedical R&D Company | Recruiting | No outcome recorded |
| Phase 1 | NCT07414953 | Mar 2026 → Apr 2027 expected | lung cancer | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06927570 | Apr 2025 → Jan 2028 expected | cancer | Hansoh BioMedical R&D Company | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HS-20122 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07414953 ↗ |
| Route | Intravenous | “Intravenous (IV) administration of HS-20122” NCT06927570 ↗ |